Suryasarathi Dasgupta
Scientific Director, Precision Medicine Immunology Abbvie
Seminars
Thursday 2nd April 2026
Redefining Success in IBD Clinical Trials by Investigating Mechanism of Therapeutic Response/Non-Response & Driving Innovation
1:30 pm
- Highlight the limitations of existing treatments in achieving full remission
- Show how residual disease activity leads to complications like fibrosis, fistulas, and surgery
- Explore how precision endpoints and biomarker-guided trials can improve therapeutic targeting
